CYBERDYNE Inc.

Equities

7779

JP3311530004

Healthcare Facilities & Services

Delayed Japan Exchange Other stock markets 09:39:32 17/05/2024 am IST			5-day change	1st Jan Change
194 ^JPY	-1.02%		-4.43%	-13.39%

15/05	U.S. FDA Becomes the world's First to Clear Smaller Model of Medical HAL and Expanded Indication for Cerebral Palsy	CI
30/04	Cyberdyne May Book 18 Million Yen Provision for Doubtful Accounts in Fiscal 2024 Due to Non-collectable Claims	MT

Metcela Inc. announced that it has received ¥1.87 billion in funding from CYBERDYNE Inc., CEJ Capital Co., Ltd., Japan Lifeline Co., Ltd., Sony Ventures Corporation, Reazon Holdings, Inc.

June 28, 2022

Metcela Inc. announced that it has received ¥1,870,000,000 in a round of funding led by CYBERDYNE Inc. and Cybernics Excellence Japan No.1 Fund, a fund managed by CEJ Capital Co., Ltd. on June 28, 2022. The transaction included participation from Reazon Holdings, Inc. and returning investor Sony Ventures Corporation and Japan Lifeline Co., Ltd.

Latest news about CYBERDYNE Inc.

U.S. FDA Becomes the world's First to Clear Smaller Model of Medical HAL and Expanded Indication for Cerebral Palsy	15/05	CI
Cyberdyne May Book 18 Million Yen Provision for Doubtful Accounts in Fiscal 2024 Due to Non-collectable Claims	30/04	MT
CYBERDYNE Inc. Signs Business Consignment Agreement with New Energy and Industrial Technology Development Organization	15/02	CI
Cyberdyne Foresees Potential Bad Debt Loss Amid OCT's Bankruptcy Proceedings	29/12	MT
Cyberdyne to Sign a Consignment Agreement with NEDO; Expects 332 Million Yen in Other Income for Fiscal 2023	06/12	MT
Cyeberdyne Appoints Shinji Honda as New Executive Director and COO	05/12	MT
CYBERDYNE Inc. Appoints Shinji Honda as New Executive Director and Chief Operating Officer, Effective December 18, 2023	04/12	CI
Cyberdyne Books 660 million Yen in Impairment Loss in Fiscal Q2	15/11	MT
Cyberdyne Secures Grant for Development of Robotic Care Device Overseas	09/23/09	MT
Certain Common Stock of Cyfuse Biomedical K.K. are subject to a Lock-Up Agreement Ending on 1-JUN-2023.	01/23/01	CI
CYBERDYNE Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	15/23/15	CI
CYBERDYNE Inc. completed the acquisition of 8% stake in LeyLine GmbH from Midori Moriwaki.	31/23/31	CI
Cyberdyne to Take Controlling Stake in German Racing Team Operator	30/23/30	MT
CYBERDYNE Inc. signed an agreement to acquire 8% stake in LeyLine GmbH from Midori Moriwaki.	29/23/29	CI
Certain Common Stock of Cyfuse Biomedical K.K. are subject to a Lock-Up Agreement Ending on 28-FEB-2023.	28/23/28	CI
Cyberdyne Repurchases 1.2 Billion Yen Worth of Stock; Shares Gain 4%	21/23/21	MT
Tranche Update on CYBERDYNE Inc.'s Equity Buyback Plan announced on February 20, 2023.	21/23/21	CI
CYBERDYNE Inc.'s Equity Buyback announced on February 20, 2023, has closed with 4,000,000 shares, representing 1.86% for ¥1,188 million.	21/23/21	CI
CYBERDYNE Inc. announces an Equity Buyback for 4,000,000 shares, representing 2.91% for ¥1,188 million.	20/23/20	CI
CYBERDYNE Inc. authorizes a Buyback Plan.	20/23/20	CI
Cyberdyne Inc. Announces Yuzo Toda Passed Away on December 27, 2022, and Retired from the Position of Director on the Same Day	06/23/06	CI
Cyfuse Biomedical K.K. has completed an IPO in the amount of Ã‘2.477466 billion.	01/22/01	CI
Cyfuse Biomedical K.K. has filed an IPO.	27/22/27	CI
Hirosaki Lifescience Innovation, Inc. announced that it has received funding from CYBERDYNE Inc.	17/22/17	CI
Xenoma, Inc. announced that it has received funding from CYBERDYNE Inc.	10/22/10	CI

Chart CYBERDYNE Inc.

Duration

Period

More charts

Company Profile

Cyberdyne Inc is engaged in the research, development, manufacture, sale, and maintenance management related to Cybernics technology. The Company mainly uses human and the Internet of Things (IoH/IoT), robots, and artificial intelligence (AI) Cybernics technology to develop Cybernic systems. It develops the Cybernics treatment service business and the training service business that utilize Cybernics technology. The Company develops in various fields centered on HAL. HAL is a robot treatment device for the purpose of improving and regenerating the physical function of patients, a welfare device and life support device for the purpose of supporting independence, and a work support equipment. It can be used for various purposes by being worn and used by people. The Company is also involved in the productization of AI-equipped transport robots; cleaning robots; Cyin, which is used for communication with people with disabilities, and electrocardiography devices.

Sector

Healthcare Facilities & Services

Calendar

14/08/2024 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for CYBERDYNE Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

196 JPY

Average target price

320 JPY

Spread / Average Target

+63.27%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
CYBERDYNE INC.	-13.39%	27Cr
HCA HEALTHCARE, INC.	+19.22%	8.56TCr
CVS HEALTH CORPORATION	-27.14%	7.06TCr
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+4.65%	2.7TCr
LABORATORY CORPORATION OF AMERICA HOLDINGS	-6.23%	1.8TCr
FRESENIUS SE & CO. KGAA	+1.60%	1.76TCr
QUEST DIAGNOSTICS INCORPORATED	+3.30%	1.56TCr
REDE D'OR SÃO LUIZ S.A.	+7.44%	1.35TCr
FRESENIUS MEDICAL CARE AG	+9.91%	1.34TCr
NATERA, INC.	+73.32%	1.32TCr

Other Healthcare Facilities & Services